PAR •
Healthcare •
Biotechnology •
Quote as of 08/18/2026 15:27
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangePAR
Market Capitalization4.31 mln
Float23.36 mln
Earnings Date06/10/2025
Piotroski F-Score
2
/ 9
Weak
Relative Strength
100
/ 100
Top performer
Debt / Equity
-0.94
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
Business Description
Biophytis S.A. is a Paris-based biotechnology company founded in 2006 that develops treatments aimed at slowing the effects of aging-related conditions, including muscle-wasting diseases and respiratory complications. Its primary drug candidate, BIO101, is being studied as a potential treatment for conditions such as sarcopenia, Duchenne Muscular Dystrophy, and severe respiratory illness linked to COVID-19. The company works alongside AFM-Telethon to advance BIO101 for Duchenne Muscular Dystrophy and has partnered with LynxKite Technologies to apply artificial intelligence to the discovery of new longevity therapies.
